MB49-luc Cell Line

Tool Details

*FOR RESEARCH USE ONLY

• Name: MB49-luc Cell Line
• Alternate name: MB49-luciferase, MB49-luc, MB-49-Luc, MB49luc, MB-49-luc, MB49-LUC, MB49 Luciferase (firefly) Cells
• Parental cell: MB49 Cell Line
• Organism: Mouse
• Gender: Male
• Tissue: Bladder
• Disease: Cancer
• Morphology: Epithelial cells
• Growth properties: Adherent
• Model: Tumourigenic line
• Crispr: No
• Conditional: No
• Description: MB49-luc is an aggressive, bioluminescent orthotopic bladder cancer model stably expressing luciferase, derived from the well-established MB49 cell line. The bioluminescence can be detected by in vivo imaging and offers a readout for tumour take, growth and reduction. Similarly to its parental cell line MB49 (Cat. #: 153368), it forms tumours when injected subcutaneously or orthotopically into mouse bladders. Specifically, the orthotopic intravesical bladder tumour model based on MB49-luc offers a system to study immune-related factors involved in non-muscle invasive, non-metastatic bladder tumour growth, including anti-tumour effects of treatments such as immune checkpoint inhibitors. It also provides a bladder cancer model to study mechanisms of immunotherapy non-responders, to help identifying effective immune-based combination therapies and PD-L1 function within a tumour microenvironment devoid of T cells.
• Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
• Production details: Parental MB49 cells transfected with a pSELECT-zeo-LucSh plasmid using Lipofectamine (InvivoGen) for luciferase expression detected by in vivo imaging
• Biosafety level: 1

Target Details

• Target: PD-1, the programmed death-1 receptor
• Target background: The programmed death-1 (PD-1) receptor is a checkpoint inhibitor, that interacts with distinct ligands, PD-L1 (B7-H1, CD274). PD-L1 is expressed on a wide variety of human and mouse tumour cells and some immune cell populations

Applications

• Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
• Application notes: Identification host antitumor immune mechanisms and evaluation combinations of immune-based therapies for carcinoma in situ and non–muscle invasive, non-metastatic urothelial carcinoma

Handling

• Growth medium: Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated foetal bovine serum supplemented with 1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, and penicillin/streptomycin (100 U/mL).
• Temperature: 37° C
• Atmosphere: 5% CO2
• Shipping conditions: Dry Ice
• Storage conditions: Liquid Nitrogen
• Mycoplasma free: Yes

Related Tools

• Related tools: MB49 Cell Line

References

• Domingos-Pereira et al. Int J Mol Sci. 2022. 24(1):123. PMID: 36613562.
• Vandeveer et al. Cancer Immunol Res. 2016. 4(5):452-462. PMID: 26921031.